RT Journal Article
SR Electronic
T1 Utility in Clinical Trials of Magnetic Resonance Imaging for Psoriatic Arthritis: A Report from the GRAPPA 2014 Annual Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1044
OP 1047
DO 10.3899/jrheum.150130
VO 42
IS 6
A1 Mikkel Østergaard
A1 Daniel Glinatsi
A1 Susanne Juhl Pedersen
A1 Inge Juul Sørensen
YR 2015
UL http://www.jrheum.org/content/42/6/1044.abstract
AB Psoriatic arthritis (PsA) is a heterogeneous disease that involves both peripheral and axial joints and entheses. Magnetic resonance imaging (MRI) allows visualization of the inflammatory components (synovitis, tenosynovitis, enthesitis, periarticular inflammation, and bone marrow edema) as well as structural damage (bone erosion, bone proliferation) in PsA. However, MRI has not been validated as an outcome measure in PsA clinical trials to the same extent as in rheumatoid arthritis. Recently, further validation of the Outcome Measures in Rheumatology (OMERACT) PsA MRI score (PsAMRIS) was presented at the 2014 annual meeting of the Group for Research and Assessment of Psoriatic Arthritis (GRAPPA). In this review, we present the current knowledge within MRI assessment of PsA, particularly peripheral manifestations, as well as different imaging methods and scoring systems, and we discuss future research perspectives.